BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37432960)

  • 1. Assessing a biomarker's ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study.
    Pritchett MA; Sigal B; Bowling MR; Kurman JS; Pitcher T; Springmeyer SC;
    PLoS One; 2023; 18(7):e0287409. PubMed ID: 37432960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
    Silvestri GA; Tanner NT; Kearney P; Vachani A; Massion PP; Porter A; Springmeyer SC; Fang KC; Midthun D; Mazzone PJ;
    Chest; 2018 Sep; 154(3):491-500. PubMed ID: 29496499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study.
    Lee HJ; Mazzone P; Feller-Kopman D; Yarmus L; Hogarth K; Lofaro LR; Griscom B; Johnson M; Choi Y; Huang J; Bhorade S; Spira A; Kennedy GC; Wahidi MM;
    Chest; 2021 Jan; 159(1):401-412. PubMed ID: 32758562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.
    Vachani A; Hammoud Z; Springmeyer S; Cohen N; Nguyen D; Williamson C; Starnes S; Hunsucker S; Law S; Li XJ; Porter A; Kearney P
    Lung; 2015 Dec; 193(6):1023-7. PubMed ID: 26376647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules.
    Kheir F; Uribe JP; Cedeno J; Munera G; Patel H; Abdelghani R; Matta A; Benzaquen S; Villalobos R; Majid A
    J Thorac Dis; 2023 Jul; 15(7):3557-3567. PubMed ID: 37559655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer.
    Vachani A; Whitney DH; Parsons EC; Lenburg M; Ferguson JS; Silvestri GA; Spira A
    Chest; 2016 Jul; 150(1):210-8. PubMed ID: 26896702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated risk predictor for pulmonary nodules.
    Kearney P; Hunsucker SW; Li XJ; Porter A; Springmeyer S; Mazzone P
    PLoS One; 2017; 12(5):e0177635. PubMed ID: 28545097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and consequences of non-adherence to an evidence-based approach for incidental pulmonary nodules.
    Wayne MT; Prescott HC; Arenberg DA
    PLoS One; 2022; 17(9):e0274107. PubMed ID: 36084105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation.
    Tanner NT; Porter A; Gould MK; Li XJ; Vachani A; Silvestri GA
    Chest; 2017 Aug; 152(2):263-270. PubMed ID: 28115167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases.
    Liang W; Liu D; Li M; Wang W; Qin Z; Zhang J; Zhang Y; Hu Y; Bao H; Xiang Y; Wang B; Wu J; Sun J; Hu C; Ye X; Zhang X; Xiao W; Yun C; Sun D; Wang W; Chang N; Zhang Y; Zhao J; Zhang X; Xu J; Wu D; Liu X; Guo Y; Zhang Q; Zhang W; Yang L; Li Z; Zhang X; Han B; Tong Z; He J; Qu J; Fan JB; Zhong N
    Transl Lung Cancer Res; 2020 Oct; 9(5):2016-2026. PubMed ID: 33209621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CT-Guided Core Needle Biopsy in Pulmonary Ground-Glass and Solid Nodules Based on Propensity Score Matching Analysis.
    An W; Zhang H; Wang B; Zhong F; Wang S; Liao M
    Technol Cancer Res Treat; 2022; 21():15330338221085357. PubMed ID: 35297696
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study.
    Tanner NT; Aggarwal J; Gould MK; Kearney P; Diette G; Vachani A; Fang KC; Silvestri GA
    Chest; 2015 Dec; 148(6):1405-1414. PubMed ID: 26087071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening.
    Horeweg N; van Rosmalen J; Heuvelmans MA; van der Aalst CM; Vliegenthart R; Scholten ET; ten Haaf K; Nackaerts K; Lammers JW; Weenink C; Groen HJ; van Ooijen P; de Jong PA; de Bock GH; Mali W; de Koning HJ; Oudkerk M
    Lancet Oncol; 2014 Nov; 15(12):1332-41. PubMed ID: 25282285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the PanCan Model and Lung-RADS to Assess Cancer Probability Among People With Screening-Detected, Solid Lung Nodules.
    Sundaram V; Gould MK; Nair VS
    Chest; 2021 Mar; 159(3):1273-1282. PubMed ID: 33393476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a bronchial genomic classifier on clinical decision making in patients undergoing diagnostic evaluation for lung cancer.
    Ferguson JS; Van Wert R; Choi Y; Rosenbluth MJ; Smith KP; Huang J; Spira A
    BMC Pulm Med; 2016 May; 16(1):66. PubMed ID: 27184093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
    Li X; Zhang Q; Jin X; Cao L
    World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical Study of Artificial Intelligence-assisted Diagnosis System in Predicting the 
Invasive Subtypes of Early-stage Lung Adenocarcinoma Appearing as Pulmonary Nodules].
    Su Z; Mao W; Li B; Zheng Z; Yang B; Ren M; Song T; Feng H; Meng Y
    Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):245-252. PubMed ID: 35477188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative diagnosis of malignant pulmonary nodules in lung cancer screening with a radiomics nomogram.
    Liu A; Wang Z; Yang Y; Wang J; Dai X; Wang L; Lu Y; Xue F
    Cancer Commun (Lond); 2020 Jan; 40(1):16-24. PubMed ID: 32125097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.